---
title: "UBS Investment Ratings and Target Prices for Healthcare Stocks (Table)"
description: "UBS released a research report listing investment ratings and target prices for healthcare stocks. Hengrui Pharma is rated as Buy, with the target price raised from RMB 96.9 to RMB 98.3; Hansoh Pharma"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277163725.md"
published_at: "2026-02-27T07:48:10.000Z"
---

# UBS Investment Ratings and Target Prices for Healthcare Stocks (Table)

> UBS released a research report listing investment ratings and target prices for healthcare stocks. Hengrui Pharma is rated as Buy, with the target price raised from RMB 96.9 to RMB 98.3; Hansoh Pharma is rated as Buy, with the target price raised from RMB 48.2 to RMB 51.5; Sino Biopharmaceutical is rated as Buy, with a target price of RMB 12.2; 3SBIO is rated as Buy, with a target price of RMB 41; CSPC Pharma is rated as Neutral, with the target price raised from RMB 10 to RMB 10.9; Simcere Pharma is rated as Buy, with a target price of RMB 16.3; United Lab is rated as Buy, with a target price of RMB 18.9

UBS published a research report listing the investment ratings and target prices for healthcare stocks as follows:

Stock | Investment Rating | Target Price (HKD)

Hengrui Pharma (01276.HK) | Buy | 96.9 → 98.3

HANSOH PHARMA (03692.HK) | Buy | 48.2 → 51.5

SINO BIOPHARM (01177.HK) | Buy | 12.2

3SBIO (01530.HK) | Buy | 41

CSPC PHARMA (01093.HK) | Neutral | 10 → 10.9

SIMCERE PHARMA (02096.HK) | Buy | 16.3

UNITED LAB (03933.HK) | Buy | 18.9

### Related Stocks

- [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md)
- [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md)
- [159316.CN - E Fund Hang Seng SCHK Innovative Drug ETF](https://longbridge.com/en/quote/159316.CN.md)
- [516930.CN - Minsheng Royal CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516930.CN.md)
- [520880.CN - Hwabao WP Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520880.CN.md)
- [300765.CN - CSPC Innovation](https://longbridge.com/en/quote/300765.CN.md)
- [516610.CN - Dacheng CSI All Share Health Care Equipment and Services ETF](https://longbridge.com/en/quote/516610.CN.md)
- [520690.CN - Bosera Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520690.CN.md)
- [588250.CN - Penghua SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588250.CN.md)
- [589720.CN - Guotai SSE STAR Brand Name Drug ETF](https://longbridge.com/en/quote/589720.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hansoh Pharmaceutical Group Company Limited Announces Approval in the European Union as Monotherapy | Hansoh Pharmaceutical Group Company Limited announced that Aumolertinib Mesylate Tablets, known as Ameile in China, rece | [Link](https://longbridge.com/en/news/276480305.md) |
| Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | [Link](https://longbridge.com/en/news/276393466.md) |
| Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | [Link](https://longbridge.com/en/news/276822785.md) |
| CStone Wins Second UK Approval for Lung Cancer Drug Sugemalimab | CStone Pharmaceuticals has received UK approval for its lung cancer drug, sugemalimab, as a monotherapy for adult patien | [Link](https://longbridge.com/en/news/276549711.md) |
| China Medical System Gets China Acceptance for Atopic Dermatitis Drug | China Medical System Gets China Acceptance for Atopic Dermatitis Drug | [Link](https://longbridge.com/en/news/276718382.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.